Skip to content
Sexuality – Lifestyle
Author:
Nanobiotix S.A.
NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer
September 14, 2026
NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026
September 11, 2026
NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 9, 2026
Voting Rights and Shares Capital of the Company
August 25, 2026
Voting Rights and Shares Capital of the Company
July 30, 2026
Voting Rights and Shares Capital of the Company
June 5, 2026
Nanobiotix Provides First Quarter 2026 Operational and Financial Update
June 2, 2026
Nanobiotix Joins the Euronext Tech Leaders Index
June 2, 2026
NANOBIOTIX Announces Closing of Global Offering
May 26, 2026
NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
May 22, 2026
1
2
3
Next Page
→